{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T18:04:30Z","timestamp":1767117870572,"version":"3.48.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Clinical Research Promotion Grant Program of Nara Medical University","award":["JHR2400002"],"award-info":[{"award-number":["JHR2400002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04649-4","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:25:55Z","timestamp":1763983555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design and rationale for a pilot trial of D-alanine supplementation to reduce the triglyceride to high-density lipoprotein cholesterol ratio in patients with chronic kidney disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Masaru","family":"Matsui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasako","family":"Tato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Eriguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Samejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"13","key":"4649_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296\u2013305.","journal-title":"N Engl J Med"},{"issue":"9","key":"4649_CR2","doi-asserted-by":"publisher","first-page":"e1001307","DOI":"10.1371\/journal.pmed.1001307","volume":"9","author":"M Wyld","year":"2012","unstructured":"Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9):e1001307.","journal-title":"PLoS Med"},{"issue":"7","key":"4649_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrneph.2017.63","volume":"13","author":"R Vanholder","year":"2017","unstructured":"Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, Morton RL, Oberbauer R, Postma MJ, Tonelli M, et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol. 2017;13(7):393\u2013409.","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"4649_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semnephrol.2016.05.008","volume":"36","author":"V Wang","year":"2016","unstructured":"Wang V, Vilme H, Maciejewski ML, Boulware LE. The economic burden of chronic kidney disease and End-Stage renal disease. Semin Nephrol. 2016;36(4):319\u201330.","journal-title":"Semin Nephrol"},{"issue":"3","key":"4649_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.ajkd.2018.02.362","volume":"72","author":"HR Yun","year":"2018","unstructured":"Yun HR, Kim H, Park JT, Chang TI, Yoo TH, Kang SW, Choi KH, Sung S, Kim SW, Lee J, et al. Obesity, metabolic Abnormality, and progression of CKD. Am J Kidney Dis. 2018;72(3):400\u201310.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4649_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(1):120\u201331.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"4649_CR7","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.2215\/CJN.02180311","volume":"6","author":"G Thomas","year":"2011","unstructured":"Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10):2364\u201373.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4649_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40620-016-0362-x","volume":"30","author":"RJ Glassock","year":"2017","unstructured":"Glassock RJ, Denic A, Rule AD. The conundrums of chronic kidney disease and aging. J Nephrol. 2017;30(4):477\u201383.","journal-title":"J Nephrol"},{"key":"4649_CR9","doi-asserted-by":"publisher","first-page":"h6559","DOI":"10.1136\/bmj.h6559","volume":"352","author":"T Ellam","year":"2016","unstructured":"Ellam T, Twohig H, Khwaja A. Chronic kidney disease in elderly people: disease or disease label? BMJ. 2016;352:h6559.","journal-title":"BMJ"},{"key":"4649_CR10","doi-asserted-by":"crossref","unstructured":"Handelsman Y, Butler J, Bakris GL, DeFronzo RA, Fonarow GC, Green JB, Grunberger G, Januzzi JL Jr., Klein S, Kushner PR, et al. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023;37(2):108389.","DOI":"10.1016\/j.jdiacomp.2022.108389"},{"key":"4649_CR11","doi-asserted-by":"crossref","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, Kengne AP, Madero M, Mihaylova B, Tangri N, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2021;99(1):34\u201347.","DOI":"10.1016\/j.kint.2020.10.012"},{"issue":"2","key":"4649_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00380-018-1247-9","volume":"34","author":"K Yokoyama","year":"2019","unstructured":"Yokoyama K, Tani S, Matsuo R, Matsumoto N. Increased triglyceride\/high-density lipoprotein cholesterol ratio May be associated with reduction in the low-density lipoprotein particle size: assessment of atherosclerotic cardiovascular disease risk. Heart Vessels. 2019;34(2):227\u201336.","journal-title":"Heart Vessels"},{"issue":"10","key":"4649_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","volume":"139","author":"T McLaughlin","year":"2003","unstructured":"McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802\u20139.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4649_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12933-024-02464-z","volume":"23","author":"Y Tong","year":"2024","unstructured":"Tong Y, Wang Y, Chen X, Qin B, Liu Y, Cui Y, Gao X, Wang J, Wu T, Lv D, et al. The triglyceride glucose: high-density lipoprotein cholesterol ratio is associated with coronary artery calcification evaluated via non-gated chest CT. Cardiovasc Diabetol. 2024;23(1):376.","journal-title":"Cardiovasc Diabetol"},{"key":"4649_CR15","doi-asserted-by":"publisher","first-page":"504219","DOI":"10.3389\/fneur.2020.504219","volume":"11","author":"MH Woo","year":"2020","unstructured":"Woo MH, Lee KO, Chung D, Choi JW, Kim SH, Oh SH. Triglyceride\/HDL-Cholesterol ratio as an index of intracranial atherosclerosis in nonstroke individuals. Front Neurol. 2020;11:504219.","journal-title":"Front Neurol"},{"key":"4649_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2021.08.004","volume":"332","author":"T Kosugi","year":"2021","unstructured":"Kosugi T, Eriguchi M, Yoshida H, Tasaki H, Fukata F, Nishimoto M, Matsui M, Samejima KI, Iseki K, Fujimoto S, et al. Association between chronic kidney disease and new-onset dyslipidemia: the Japan specific health checkups (J-SHC) study. Atherosclerosis. 2021;332:24\u201332.","journal-title":"Atherosclerosis"},{"issue":"1","key":"4649_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.atherosclerosis.2013.12.037","volume":"233","author":"K Tsuruya","year":"2014","unstructured":"Tsuruya K, Yoshida H, Nagata M, Kitazono T, Hirakata H, Iseki K, Moriyama T, Yamagata K, Yoshida H, Fujimoto S, et al. Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population. Atherosclerosis. 2014;233(1):260\u20137.","journal-title":"Atherosclerosis"},{"issue":"6","key":"4649_CR18","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1053\/j.ajkd.2015.05.011","volume":"66","author":"K Tsuruya","year":"2015","unstructured":"Tsuruya K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C, Fujimoto S, Konta T, Moriyama T, Yamagata K, et al. Impact of the triglycerides to High-Density lipoprotein cholesterol ratio on the incidence and progression of CKD: A longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66(6):972\u201383.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"4649_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41440-023-01197-y","volume":"46","author":"T Uemura","year":"2023","unstructured":"Uemura T, Nishimoto M, Eriguchi M, Tamaki H, Tasaki H, Furuyama R, Fukata F, Kosugi T, Morimoto K, Matsui M, et al. Association of triglycerides to high-density lipoprotein cholesterol ratio with incident cardiovascular disease but not end-stage kidney disease among patients with biopsy-proven diabetic nephropathy. Hypertens Res. 2023;46(6):1423\u201332.","journal-title":"Hypertens Res"},{"key":"4649_CR20","doi-asserted-by":"crossref","unstructured":"Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Pena Genao E, Guzman E, Kostara CE. The triglyceride\/high-density lipoprotein cholesterol (TG\/HDL-C) ratio as a risk marker for metabolic syndrome and cardiovascular disease. Diagnostics (Basel) 2023;13(5).","DOI":"10.3390\/diagnostics13050929"},{"issue":"6","key":"4649_CR21","doi-asserted-by":"publisher","first-page":"109044","DOI":"10.1016\/j.jdiacomp.2025.109044","volume":"39","author":"D Voziki","year":"2025","unstructured":"Voziki D, Dimakopoulos G, Stergiou I, Zografou I, Rizzo M, Liberopoulos EN, Kotsa K, Koufakis T. The effects of SGLT2 inhibitors and GLP-1 receptor agonists on the triglyceride to HDL cholesterol ratio and the triglyceride-glucose index in patients with type 2 diabetes. J Diabetes Complications. 2025;39(6):109044.","journal-title":"J Diabetes Complications"},{"issue":"5","key":"4649_CR22","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1021\/acs.jproteome.5b01067","volume":"15","author":"J Koehbach","year":"2016","unstructured":"Koehbach J, Gruber CW, Becker C, Kreil DP, Jilek A. MALDI TOF\/TOF-Based approach for the identification of d- amino acids in biologically active peptides and proteins. J Proteome Res. 2016;15(5):1487\u201396.","journal-title":"J Proteome Res"},{"issue":"3","key":"4649_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/mdr.2012.0009","volume":"18","author":"P Horcajo","year":"2012","unstructured":"Horcajo P, de Pedro MA, Cava F. Peptidoglycan plasticity in bacteria: stress-induced peptidoglycan editing by noncanonical D-amino acids. Microb Drug Resist. 2012;18(3):306\u201313.","journal-title":"Microb Drug Resist"},{"issue":"1","key":"4649_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jb\/mvab043","volume":"170","author":"T Miyamoto","year":"2021","unstructured":"Miyamoto T, Homma H. D-Amino acid metabolism in bacteria. J Biochem. 2021;170(1):5\u201313.","journal-title":"J Biochem"},{"issue":"9","key":"4649_CR25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00726-020-02892-7","volume":"52","author":"G Chieffi Baccari","year":"2020","unstructured":"Chieffi Baccari G, Falvo S, Santillo A, Di Giacomo Russo F, Di Fiore MM. D-Amino acids in mammalian endocrine tissues. Amino Acids. 2020;52(9):1263\u201373.","journal-title":"Amino Acids"},{"issue":"1\u20132","key":"4649_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S1570-0232(02)00690-6","volume":"781","author":"K Hamase","year":"2002","unstructured":"Hamase K, Morikawa A, Zaitsu K. D-Amino acids in mammals and their diagnostic value. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;781(1\u20132):73\u201391.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"8","key":"4649_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/psc.2637","volume":"20","author":"C Ollivaux","year":"2014","unstructured":"Ollivaux C, Soyez D, Toullec JY. Biogenesis of D-amino acid containing peptides\/proteins: where, when and how? J Pept Sci. 2014;20(8):595\u2013612.","journal-title":"J Pept Sci"},{"key":"4649_CR28","doi-asserted-by":"crossref","unstructured":"Nakade Y, Iwata Y, Furuichi K, Mita M, Hamase K, Konno R, Miyake T, Sakai N, Kitajima S, Toyama T, et al. Gut microbiota-derived D-serine protects against acute kidney injury. JCI Insight. 2018;3(20).","DOI":"10.1172\/jci.insight.97957"},{"issue":"10","key":"4649_CR29","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.34067\/KID.0000832021","volume":"2","author":"A Hesaka","year":"2021","unstructured":"Hesaka A, Tsukamoto Y, Nada S, Kawamura M, Ichimaru N, Sakai S, Nakane M, Mita M, Okuzaki D, Okada M, et al. d-Serine mediates cellular proliferation for kidney remodeling. Kidney360. 2021;2(10):1611\u201324.","journal-title":"Kidney360"},{"issue":"11","key":"4649_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10157-023-02384-4","volume":"27","author":"T Kimura","year":"2023","unstructured":"Kimura T, Sakai S, Isaka Y. D-Serine as a sensor and effector of the kidney. Clin Exp Nephrol. 2023;27(11):891\u2013900.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"4649_CR31","doi-asserted-by":"publisher","first-page":"F667","DOI":"10.1152\/ajprenal.00198.2021","volume":"322","author":"Y Iwata","year":"2022","unstructured":"Iwata Y, Nakade Y, Kitajima S, Yoneda-Nakagawa S, Oshima M, Sakai N, Ogura H, Sato K, Toyama T, Yamamura Y, et al. Protective effect of d-alanine against acute kidney injury. Am J Physiol Ren Physiol. 2022;322(6):F667\u201379.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"2","key":"4649_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.34067\/KID.0000000000000345","volume":"5","author":"S Sakai","year":"2024","unstructured":"Sakai S, Tanaka Y, Tsukamoto Y, Kimura-Ohba S, Hesaka A, Hamase K, Hsieh CL, Kawakami E, Ono H, Yokote K, et al. : d -Alanine affects the circadian clock to regulate glucose metabolism in the kidney. Kidney360. 2024;5(2):237\u201351.","journal-title":"Kidney360"},{"issue":"7","key":"4649_CR33","doi-asserted-by":"publisher","first-page":"103787","DOI":"10.1016\/j.cdnut.2024.103787","volume":"8","author":"M Oshima","year":"2024","unstructured":"Oshima M, Toyama T, Toyama T, Nakade Y, Tokumaru T, Sako K, Kajikawa S, Hayashi D, Sanada H, Yuasa T, et al. Effects of d-alanine intake on amino acid metabolism and kidney function in healthy adults: A Multicenter, randomized pilot study. Curr Dev Nutr. 2024;8(7):103787.","journal-title":"Curr Dev Nutr"},{"key":"4649_CR34","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"4649_CR35","doi-asserted-by":"crossref","unstructured":"Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA, group, Pc. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ 2016;355:i5239.","DOI":"10.1136\/bmj.i5239"},{"issue":"1","key":"4649_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"8","key":"4649_CR37","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/ndt\/gfad269","volume":"39","author":"WM Zhao","year":"2024","unstructured":"Zhao WM, Li XL, Shi R, Zhu Y, Wang ZJ, Wang XR, Pan HF, Wang DG. Global, regional and National burden of CKD in children and adolescents from 1990 to 2019. Nephrol Dial Transpl. 2024;39(8):1268\u201378.","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"4649_CR38","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1681\/ASN.2014080772","volume":"26","author":"M Matsui","year":"2015","unstructured":"Matsui M, Uemura S, Takeda Y, Samejima K, Matsumoto T, Hasegawa A, Tsushima H, Hoshino E, Ueda T, Morimoto K, et al. Placental growth factor as a predictor of cardiovascular events in patients with CKD from the NARA-CKD study. J Am Soc Nephrol. 2015;26(11):2871\u201381.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4649_CR39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.2010.39","volume":"303","author":"BR Hemmelgarn","year":"2010","unstructured":"Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M. Alberta kidney disease N: relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423\u20139.","journal-title":"JAMA"},{"issue":"12","key":"4649_CR40","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"15","key":"4649_CR41","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"4649_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"E-KCG The","year":"2023","unstructured":"The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"23","key":"4649_CR43","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1806802","volume":"380","author":"PD Reaven","year":"2019","unstructured":"Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, Duckworth WC, Hayward RA, Investigators V. Intensive glucose control in patients with type 2 diabetes \u2013\u200915-Year Follow-up. N Engl J Med. 2019;380(23):2215\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"4649_CR44","doi-asserted-by":"publisher","first-page":"e012749","DOI":"10.1161\/JAHA.119.012749","volume":"8","author":"E Ku","year":"2019","unstructured":"Ku E, Sarnak MJ, Toto R, McCulloch CE, Lin F, Smogorzewski M, Hsu CY. Effect of blood pressure control on Long-Term risk of End-Stage renal disease and death among subgroups of patients with chronic kidney disease. J Am Heart Assoc. 2019;8(16):e012749.","journal-title":"J Am Heart Assoc"},{"issue":"9784","key":"4649_CR45","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, et al. The effects of Lowering LDL cholesterol with Simvastatin plus Ezetimibe in patients with chronic kidney disease (Study of heart and renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"10","key":"4649_CR46","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","volume":"4","author":"C Cholesterol Treatment Trialists","year":"2016","unstructured":"Cholesterol Treatment Trialists C, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellstrom B, Jardine AG, et al. Impact of renal function on the effects of LDL cholesterol Lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol. 2016;4(10):829\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"4649_CR47","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1681\/ASN.2013090965","volume":"25","author":"R Haynes","year":"2014","unstructured":"Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, Craig JC, de Zeeuw D, Feldt-Rasmussen B, Fellstrom B, et al. Effects of Lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25(8):1825\u201333.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4649_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10157-016-1304-6","volume":"21","author":"G Kimura","year":"2017","unstructured":"Kimura G, Kasahara M, Ueshima K, Tanaka S, Yasuno S, Fujimoto A, Sato T, Imamoto M, Kosugi S, Nakao K. Effects of Atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clin Exp Nephrol. 2017;21(3):417\u201324.","journal-title":"Clin Exp Nephrol"},{"issue":"21","key":"4649_CR49","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, et al. Triglyceride Lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923\u201334.","journal-title":"N Engl J Med"},{"key":"4649_CR50","first-page":"16","volume":"8","author":"A Cordero","year":"2009","unstructured":"Cordero A, Alegria-Ezquerra E. TG\/HDL ratio as surrogate marker for insulin resistance. E-J ESC Counc Cardiol Pract. 2009;8:16.","journal-title":"E-J ESC Counc Cardiol Pract"},{"key":"4649_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1475-2840-7-4","volume":"7","author":"C Li","year":"2008","unstructured":"Li C, Ford ES, Meng YX, Mokdad AH, Reaven GM. Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race\/ethnicity? Cardiovasc Diabetol. 2008;7:4.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"4649_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"7","key":"4649_CR53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/00365519950185229","volume":"59","author":"C Ric\u00f3s","year":"1999","unstructured":"Ric\u00f3s C, Alvarez V, Cava F, Garc\u00eda-Lario JV, Hern\u00e1ndez A, Jim\u00e9nez CV, Minchinela J, Perich C, Sim\u00f3n M. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest. 1999;59(7):491\u2013500.","journal-title":"Scand J Clin Lab Invest"},{"issue":"4","key":"4649_CR54","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.bbrc.2007.02.056","volume":"355","author":"A Morikawa","year":"2007","unstructured":"Morikawa A, Hamase K, Ohgusu T, Etoh S, Tanaka H, Koshiishi I, Shoyama Y, Zaitsu K. Immunohistochemical localization of D-alanine to beta-cells in rat pancreas. Biochem Biophys Res Commun. 2007;355(4):872\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"4649_CR55","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12882-024-03808-3","volume":"25","author":"Z Xu","year":"2024","unstructured":"Xu Z, Yang S, Cui L. Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews. BMC Nephrol. 2024;25(1):400.","journal-title":"BMC Nephrol"},{"issue":"1","key":"4649_CR56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00726-024-03421-6","volume":"56","author":"T Kimura","year":"2024","unstructured":"Kimura T, Sakai S, Horio M, Takahara S, Ishigo S, Nakane M, Negishi E, Imoto H, Mita M, Hamase K, et al. Kinetic analysis of D-Alanine upon oral intake in humans. Amino Acids. 2024;56(1):61.","journal-title":"Amino Acids"},{"issue":"3","key":"4649_CR57","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF00480596","volume":"125","author":"Y Oka","year":"1977","unstructured":"Oka Y, Matsuda I, Nambu H, Nagai B, Mitsuyama T. The effects of oral alanine administration on blood glucose, pyruvate, lactate, serum glucagon and insulin in human newborns. Eur J Pediatr. 1977;125(3):191\u20135.","journal-title":"Eur J Pediatr"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04649-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04649-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04649-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T18:01:57Z","timestamp":1767117717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04649-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4649"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04649-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval to conduct this study has been granted by the Nara Medical University Clinical Research Review Committee (CRB5200002). The protocol has been made available to the public on the website of the Japan Registry of Clinical Trials (jRCTs051240262) and is adherent to the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Availability of Data and Materials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study is being conducted with the provision of the investigational drug and specialized testing services from KAGAMI INC.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"714"}}